Cite
HARVARD Citation
Liu, J. et al. (2020). Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. Journal for immunotherapy of cancer. 8 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Liu, J. et al. (2020). Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. Journal for immunotherapy of cancer. 8 (1), p. . [Online].